Julie Renee Brahmer MD

Thoracic Cancer

Professor of Oncology, Johns Hopkins University School of Medicine; Interim director, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus), Co-Director, Upper Aerodigestive Program

Join to View Full Profile

300 Mason Lord DriveKimmel Cancer CenterBaltimore, MD 21224
Phone+1 410-550-1711
Fax+1 410-550-1116

Summary

Dr. Julie Brahmer is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. She received her medical degree from University of Nebraska College of Medicine and has been in practice 24 years. She specializes in thoracic oncology and is experienced in gastrointestinal oncology, and general medical oncology.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Utah HealthResidency, Internal Medicine, 1993 - 1997
University of Nebraska College of MedicineClass of 1993

Certifications & Licensure

FL State Medical License 2021 - Present
DC State Medical License 2022 - 2027
MD State Medical License 1997 - 2026
PA State Medical License 2024 - 2026
VA State Medical License 2023 - 2026
UT State Medical License 1994 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Fellow (FASCO) American Society of Clinical Oncologists, 2011

Clinical Trials

Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
Completed
Not Applicable
Broccoli Sprout Extract in Preventing Lung Cancer in Smokers Start of enrollment: 2005 Jan 01
Completed
Not Applicable
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Start of enrollment: 2010 Apr 12
Completed
Phase 3
Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
Completed
Phase 1
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma Start of enrollment: 2011 Jun 01
Completed
Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer Start of enrollment: 2013 Mar 11
Completed
Not Applicable
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2013 May 01
Terminated
Phase 2
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
ACTIVE_NOT_RECRUITING
PHASE2
Genetic Predictors of Benefit to Pembrolizumab Start of enrollment: 2016 May 31
Terminated
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Pan Tumor Rollover Study Start of enrollment: 2019 Aug 09
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Prevalence, treatment patterns, and survival of patients with brain metastases from small cell lung cancer: A retrospective study using the TriNetX Oncology Database.
Megan Parker, Anita Kalluri, Kelly Jiang, Joshua Materi, Tej D Azad
Neuro-Oncology Practice. 2025-04-01
Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritis.
Elise F Gray-Gaillard, Ami A Shah, Clifton O Bingham Iii, Jennifer H Elisseeff, Joseph Murray
Arthritis Research & Therapy. 2025-04-01
1 citations
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01

Journal Articles

Immune-Related (IR)-Pneumonitis During the COVID-19 Pandemic: Multidisciplinary Recommendations for Diagnosis and Management
Joshua E Reuss, Karthik Suresh, David Feller-Kopman, Clare Rock, Julie R Brahmer, Journal For Immunotherapy of Cancer

Lectures

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.
2019 ASCO Annual Meeting - 6/1/2019
General Management of Immune-Related Toxicities Incorporating Guidelines Into Practice
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Emerging Strategies in Treatment of Non−Small-Cell Lung Cancer and Head & Neck Cancer 2012
CancerNet, LLC, Atlanta, Georgia - 6/16/2012

Authored Content

Evaluation of Health-Related Quality of Life and Symptoms in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or Docetaxel in CheckMate 057September 2018

Press Mentions

Cancer Immunotherapy–Related Adverse Effects Prompt Call for More ProgressJanuary 27th, 2025
Initiative for Managing Adverse Events of Immunotherapy Leads to Clinical Practice Changes at MD AndersonApril 4th, 2023
Cancer Research Institute Virtual Immunotherapy Patient Summit Is Now Available Free, on-DemandDecember 8th, 2022
Join now to see all